# LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

> **NCT00525148** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 129 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00525148
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-02
- **Final completion:** 2015-08
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525148, "LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00525148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*